Systimmune reported that izalontamab brengitecan (iza‑bren) met both progression‑free survival and overall survival endpoints in a phase‑III trial of Chinese patients with advanced triple‑negative breast cancer. The result supports the licensee’s clinical strategy and could accelerate regional registrations and commercialization discussions with global partners. The dual PFS and OS readouts strengthen the agent’s profile in a difficult‑to‑treat population and illustrate how successful late‑stage trials in China can create distinct regulatory and commercial pathways for oncology drugs globally.